$HONBullishMed

Goldman Sachs Remains Bullish on Honeywell (HON) Ahead of Aerospace Spin-Off

Goldman Sachs analyst Joe Ritchie raised Honeywell’s (HON) price target to $276 from $258 and kept a Buy rating, citing the planned Aerospace separation staying on schedule for June 29. The note says automation will become Honeywell Technologies and aerospace will trade as HONA, with lower stranded costs and upcoming investor events supporting valuation. Barclays also raised its target to $251 and maintained Overweight.

Med
Bullish
Ahead of June 29 aerospace separation
Bullish (Buy ratings and raised targets from Goldman and Barclays)

Near-term sentiment tailwind as investors position for the June 29 spin-off and valuation reset; watch for any execution slip or cost surprises.

Goldman raised Honeywell’s price target to $276 and reiterated Buy ahead of the June 29 aerospace separation, citing lower stranded costs and upcoming investor events.

Mildly positive bias into the June 29 separation date; volatility likely around investor events and any spin-off details.

Background

Honeywell is planning an aerospace separation; the automation business will become Honeywell Technologies, while the aerospace business will trade under ticker HONA after the split.

Why it matters

This note frames the spin-off as on-schedule and supported by lower-than-expected stranded costs, with multiple investor events and an external IPO filing used as a valuation reference—together reinforcing bullish positioning into the separation date.

Market relevance

Bullish sell-side reinforcement ahead of a specific corporate action date (June 29) that can drive valuation and trading volatility.

Market effects

Supports the broader aerospace/industrial spin-off and restructuring narrative; may improve sentiment for industrial conglomerates executing separations.

Primarily US large-cap industrial sentiment; limited direct regional spillover beyond US-listed peers.

Spin-off valuation and restructuring benchmarks can influence global industrial M&A/spin-off comps, but impact is indirect.

Alternative perspectives

Analyst target hikes may already be priced; execution risk around the separation schedule or stranded-cost assumptions could cap upside.

The article references Quantinuum’s IPO filing as a valuation benchmark, but it may be a weak/indirect comparator versus Honeywell’s own standalone fundamentals post-spin.

Key entities

  • Honeywell International Inc.

    Subject of analyst target raises and the planned June 29 aerospace separation.

  • Goldman Sachs

    Raised Honeywell’s price target to $276 and maintained Buy, citing spin-off execution and cost outlook.

  • Barclays

    Raised Honeywell’s price target to $251 and maintained Overweight, highlighting catalysts ahead of the spin-offs.

Related articles

$HONLow

Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split

The article says the Iran-related disruption is pressuring commercial aerospace, with high and volatile jet-fuel costs leading airlines to delay aircraft purchases and costly maintenance. It argues this could hurt Honeywell Aerospace, which it says is used across most commercial and defense aircraft. It also notes Honeywell Automation’s robotics exposure, citing a source that projects 46% CAGR growth for robotics from 2025–2034.

$HONMed

HONEYWELL BOARD OF DIRECTORS SETS RECORD DATE AND ANNOUNCES EXPECTED TIMING FOR SPIN-OFF OF HONEYWELL AEROSPACE AND HONEYWELL REVERSE STOCK SPLIT

Honeywell (NASDAQ: HON) set a June 15, 2026 record date for its previously announced spin-off of Honeywell Aerospace. The company expects to distribute shares on June 29, 2026 at a 1-for-2 ratio, with Honeywell Aerospace starting Nasdaq trading under “HONA.” Honeywell also plans a 1-for-2 reverse stock split effective June 29, 2026, reducing HON shares from ~634 million to ~317 million.

$GSMed

Dow industrial average is surging led by financials in healthcare.

The Dow Jones Industrial Average rose about 930 points, or 1.84%, with 25 of 30 components higher and the index on pace for a record close. Financials led, including Goldman Sachs (+4.93%), JPMorgan (+3.64%) and American Express (+4.41%), while healthcare also supported gains such as UnitedHealth (+5.20%) and Merck (+3.73%). Decliners included Verizon (-2.44%) and IBM (-1.10%).